Novartis AG (FRA:NOT0) Interest Expense: €-1,046 Mil (TTM As of Mar. 2026)

What is Novartis AG Interest Expense?

Novartis AG FRA:NOT0 83 Interest Expense is €-1,046 Mil as of Mar. 2026. GuruFocus rates FRA:NOT0 with a GF Score™ of 83/100 and a GF Value™ of €15.09 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Novartis AG's interest expense for the three months ended in Mar. 2026 was € -297 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-1,046 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Novartis AG's Operating Income for the three months ended in Mar. 2026 was € 3,663 Mil. Novartis AG's Interest Expense for the three months ended in Mar. 2026 was € -297 Mil. Novartis AG's Interest Coverage for the quarter that ended in Mar. 2026 was 12.35. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Novartis AG (FRA:NOT0) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Novartis AG's Interest Expense for the three months ended in Mar. 2026 was €-297 Mil. Its Operating Income for the three months ended in Mar. 2026 was €3,663 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €33,830 Mil.

Novartis AG's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2026 )	/	Interest Expense (Q: Mar. 2026 )
	=	-1	*	3663.275	/	-296.695
	=	12.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Novartis AG Interest Expense Historical Data

* Premium members only.

The historical data trend for Novartis AG's Interest Expense can be seen below:

Novartis AG Interest Expense Chart

Novartis AG Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Interest Expense

Get a 7-Day Free Trial

-696.50

-755.20

-784.04

-960.73

-976.98

Novartis AG Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Interest Expense	Get a 7-Day Free Trial															-249.75	-250.56	-239.41	-259.62	-296.70

83GF Score

Novartis AG FRA:NOT0

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Novartis AG Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1,046 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of €-1,046 Mil mean?

Novartis AG (FRA:NOT0) has a Interest Expense of €-1,046 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Novartis AG and its competitors.

Is Novartis AG's Interest Expense too high?

Novartis AG's current Interest Expense is €-1,046 Mil. Overall, Novartis AG has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Novartis AG's Interest Expense compare to LLY and JNJ?

Novartis AG's Interest Expense of €-1,046 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Drug Manufacturers company?

A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Novartis AG and its competitors. Novartis AG's current Interest Expense is €-1,046 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Novartis AG stock overvalued right now?

Based on GuruFocus' analysis, Novartis AG (FRA:NOT0) is currently considered Modestly Overvalued. The stock's GF Value™ is €15.09, compared to a current price of €18.20 — trading 20.6% above its estimated fair value. The current Interest Expense is €-1,046 Mil. Novartis AG's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For Novartis AG (FRA:NOT0), the current Interest Expense is €-1,046 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis AG (FRA:NOT0) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of €18.20 is trading 20.6% above its estimated GF Value™ of €15.09. GuruFocus considers Novartis AG to be Modestly Overvalued.

Key valuation signals for FRA:NOT0:

Interest Expense: €-1,046 Mil
GF Value™: €15.09 vs. price of €18.20 (20.6% above fair value)
GF Score™: 83/100 with 7 warning signs

No single metric tells the full story. See the FRA:NOT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novartis AG Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies XSWX:ROP XSWX:COPN LLY JNJ ABBV MRK LSE:AZN OCSE:NOVO B AMGN GILD PFE BMY LSE:GSK XPAR:SAN TSE:4519 XTER:BAYN TSE:4578 BIIB TSE:4568 TSE:4503

Other Exchanges NVSEF:USA NVS:USA NOVNN:Mexico NVSN:Mexico 1NOVN:Italy NOVNz:UK 0K9E:UK 0QLR:UK NOT:Germany NOVN:Switzerland NVS:Canada N1VS34:Brazil NVS:Argentina

Address Lichtstrasse 35, Basel, CHE, 4056

Website https://www.novartis.com

Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.

83GF Score

Get the complete analysis for FRA:NOT0

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.20

Price

€15.09

GF Value

View FRA:NOT0 Analysis

See Interest Expense data for all stocks →